Daxor Corporation announced a new research letter in the Journal of the American College of Cardiology â Heart Failure validating the benefits of the Companyâs BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. The study, titled âDiscordant Pressure-Volume Trends During CardioMEMS Monitoring,â evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxorâs blood volume analysis (BVA) diagnostic.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.7 USD | +3.19% | +3.19% | +1.04% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.04% | 46.53M | |
+7.14% | 13.19B | |
+10.99% | 9.46B | |
+1.10% | 5.65B | |
+9.70% | 5.64B | |
+7.41% | 5.28B | |
+33.17% | 5.22B | |
+26.13% | 4.82B | |
+2.65% | 4.08B | |
+5.75% | 3.99B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy